Humacyte/$HUMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Humacyte
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Advanced Organ Systems, Advanced Tissue Constructs.
Ticker
$HUMA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
219
ISIN
US44486Q1031
Website
Humacyte Metrics
BasicAdvanced
$430M
-
-$0.65
1.64
-
Price and volume
Market cap
$430M
Beta
1.64
52-week high
$9.97
52-week low
$1.15
Average daily volume
4.3M
Financial strength
Current ratio
3.68
Quick ratio
3.162
Long term debt to equity
215.898
Total debt to equity
228.927
Interest coverage (TTM)
-9.04%
Management effectiveness
Return on assets (TTM)
-42.82%
Return on equity (TTM)
-249.75%
Valuation
Price to revenue (TTM)
666.025
Price to book
11.92
Price to tangible book (TTM)
11.92
Price to free cash flow (TTM)
-3.416
Growth
Earnings per share change (TTM)
-35.93%
3-year revenue growth (CAGR)
-27.22%
3-year earnings per share growth (CAGR)
16.92%
What the Analysts think about Humacyte
Analyst ratings (Buy, Hold, Sell) for Humacyte stock.
Humacyte Financial Performance
Revenues and expenses
Humacyte Earnings Performance
Company profitability
Humacyte News
AllArticlesVideos
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
GlobeNewsWire·2 weeks ago
Humacyte, Inc. (HUMA) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 weeks ago
Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Humacyte stock?
Humacyte (HUMA) has a market cap of $430M as of May 30, 2025.
What is the P/E ratio for Humacyte stock?
The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of May 30, 2025.
Does Humacyte stock pay dividends?
No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of May 30, 2025.
When is the next Humacyte dividend payment date?
Humacyte (HUMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Humacyte?
Humacyte (HUMA) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.